|
(1) Intestinal Organoid Models for APC LOH
|
5R21CA208638-02
|
$192,406
|
GIARDINA, CHARLES
|
UNIVERSITY OF CONNECTICUT STORRS
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
2U54CA163071-06
|
$1,427,230
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
2U54CA163071-06
|
$1,427,230
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S1
|
$48,687
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S2
|
$85,299
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S3
|
$47,040
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
5U54CA163071-07
|
$1,619,382
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) University of Guam/University of Hawaii Cancer Center Partnership
|
5U54CA143727-08
|
$1,188,362
|
PALAFOX, NEAL
|
UNIVERSITY OF HAWAII AT MANOA
|
|
(1/2) University of Guam/University of Hawaii Cancer Center Partnership
|
5U54CA143727-08
|
$1,188,362
|
PALAFOX, NEAL
|
UNIVERSITY OF HAWAII AT MANOA
|
|
(1/2) University of Guam/University of Hawaii Cancer Center Partnership
|
5U54CA143727-09
|
$1,119,110
|
PALAFOX, NEAL
|
UNIVERSITY OF HAWAII AT MANOA
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-08
|
$704,474
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-08
|
$704,474
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-09
|
$714,423
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership
|
1U54CA221704-01A1
|
$1,050,067
|
OGUNWOBI, OLORUNSEUN
|
HUNTER COLLEGE
|
|
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
|
1R01CA227473-01
|
$580,767
|
HEROLD, KEVAN
|
YALE UNIVERSITY
|
|
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
|
3R01CA227473-01S1
|
$293,469
|
HEROLD, KEVAN
|
YALE UNIVERSITY
|
|
(ACCSIS) Accelerating Colorectal Cancer Screening through Implementation Science in Appalachia
|
1UG3CA233282-01
|
$770,562
|
DIGNAN, MARK
|
UNIVERSITY OF KENTUCKY
|
|
(PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbidities
|
1R01CA216290-01
|
$338,903
|
PYTER, LEAH
|
OHIO STATE UNIVERSITY
|
|
(PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbidities
|
5R01CA216290-02
|
$309,819
|
PYTER, LEAH
|
OHIO STATE UNIVERSITY
|
|
(PQ 9) Dysregulation of epidermal MMP-13 as cause of paclitaxel-induced peripheral neuropathy
|
1R01CA215973-01
|
$443,022
|
RIEGER, SANDRA
|
MOUNT DESERT ISLAND BIOLOGICAL LAB
|
|
(PQ 9) Synaptic basis of deficits in attention and executive function following cranial radiation
|
5R01CA208535-02
|
$451,564
|
GROSSHANS, DAVID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ 9) Synaptic basis of deficits in attention and executive function following cranial radiation
|
5R01CA208535-03
|
$506,533
|
GROSSHANS, DAVID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ#9): Altered mitochondrial transport and chemotherapy-induced peripheral neuropathy
|
1R21CA215985-01
|
$198,000
|
CHANG, KAREN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
(PQ#9): Altered mitochondrial transport and chemotherapy-induced peripheral neuropathy
|
5R21CA215985-02
|
$165,000
|
CHANG, KAREN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
3R01CA206025-03S1
|
$52,355
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
5R01CA206025-02
|
$637,172
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
5R01CA206025-03
|
$630,724
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance
|
1R01CA231283-01
|
$501,220
|
LIPKIN, STEVEN
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation
|
5R01CA206026-02
|
$356,850
|
WALDMAN, SCOTT
|
THOMAS JEFFERSON UNIVERSITY
|
|
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation
|
5R01CA206026-03
|
$356,850
|
WALDMAN, SCOTT
|
THOMAS JEFFERSON UNIVERSITY
|
|
(PQ11) Dietary strategies to enhance FOLFOX cancer therapies
|
1R21CA231255-01
|
$189,744
|
ROSENBERG, DANIEL
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-02
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-03
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)
|
1R01CA231267-01
|
$460,814
|
FEHRENBACHER, JILL
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ12) Peroxisome proliferator-activated receptor alpha agonists as potential treatment for chemotherapy-induced peripheral neuropathy
|
1R01CA219637-01A1
|
$281,441
|
DAMAJ, M IMAD
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
1R01CA219880-01
|
$697,539
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
5R01CA219880-02
|
$670,182
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression
|
1R01CA231112-01
|
$576,627
|
CHEN, SIDI
|
YALE UNIVERSITY
|
|
(PQ4)HIV and Aging Mechanisms for Hepatocellular Cancer
|
5R01CA206465-02
|
$527,068
|
JUSTICE, AMY
|
YALE UNIVERSITY
|
|
(PQ4)HIV and Aging Mechanisms for Hepatocellular Cancer
|
5R01CA206465-03
|
$512,833
|
JUSTICE, AMY
|
YALE UNIVERSITY
|
|
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa
|
5R01CA217138-02
|
$723,817
|
WARREN, EDUS
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa
|
1R21CA217137-01
|
$209,093
|
EL-MALLAWANY, NADER
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa
|
5R21CA217137-02
|
$196,947
|
EL-MALLAWANY, NADER
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa
|
5R21CA217137-02
|
$196,947
|
EL-MALLAWANY, NADER
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
3R01CA205967-03S2
|
$230,366
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
5R01CA205967-03
|
$386,588
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
(PQ6) Roles of circadian rhythms in tumor development
|
1R21CA227379-01
|
$208,800
|
HONG, CHRISTIAN
|
UNIVERSITY OF CINCINNATI
|
|
(PQ6): Is Adrenergic Stress-induced Immune Suppression at the Crossroads of Circadian Rhythm Disruption and Cancer?
|
1R21CA227375-01
|
$224,199
|
REPASKY, ELIZABETH
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis
|
1R01CA230848-01
|
$442,560
|
FU, LONING
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ7) In Vivo Cellular Optical Imaging of Esophageal Tumors and Microenvironment
|
5R01CA205431-02
|
$529,795
|
PERELMAN, LEV
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|